PARIS — Over the last 15 years, LASIK has been gradually losing ground in favor of other refractive surgery techniques. “We don’t know yet whether this is due to a decline of LASIK or to the emergence of new alternative techniques that broaden the indications of refractive surgery,” Michael Assouline MD, said at the meeting of the French Society of Ophthalmology. A retrospective analysis of the 52,000 cases of refractive surgery performed in his clinic since 1999 showed that the share of LASIK has gone down from 96% to less (Read more...)
Metformin Linked to Reduced Risk for Glaucoma
The geroprotective effects of the diabetes drug, which mimic caloric restriction, might help prevent late-onset open-angle glaucoma. Medscape Medical News
Santen to purchase Merck’s ophthalmology products in Japan and Europe, Asia-Pacific markets
Santen Pharmaceutical and Merck have entered into an agreement by which Santen will purchase Merck’s ophthalmology products in Japan and key markets in Europe and the Asia-Pacific. Under the agreement, Santen will purchase Cosopt (dorzolamide hydrochloride–timolol maleate ophthalmic solution), Cosopt PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution 2%/0.5%), Trusopt (dorzolamide hydrochloride ophthalmic solution sterile ophthalmic solution 2%)
First Edition: May 13, 2014
Today’s headlines include reports about how the insurance marketplace is taking shape for 2015.
Trachoma Gold Medal lecturer reports success of trachoma eradication strategy in Morocco
PARIS — Following implementation of the SAFE strategy and a system of epidemiologic surveillance, Morocco is close to achieving World Health Organization certification of elimination of blinding trachoma as a public health problem. Abdelouahed Amraoui, MD, professor of ophthalmology at the University of Casablanca, was awarded the Trachoma Gold Medal during the annual meeting of the French Society of Ophthalmology.
Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma
Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.